Table III.
Diagnostic procedures.
| Procedures | Patients |
|---|---|
| Biopsy, n (%), (n=448a) | |
| Incisional | 135 (30.1) |
| Excisional | 267 (59.6) |
| Fine-needle aspiration | 67 (15.0) |
| Core-needle biopsy | 69 (15.4) |
| Biopsy, n (%), (n=448) | |
| 1 procedure | 367 (81.9) |
| 2 repeat biopsies | 72 (16.1) |
| 3 repeat biopsies | 9 (2.0) |
| Immunohistochemistry, n (%), (n=459) | |
| Synaptophysin | |
| Performed | 367 (79.9) |
| Positive | 360 (78.4) (98.1b) |
| Negative | 7 (1.5) (1.9b) |
| Not performed | 92 (20.1) |
| Chromogranin A | |
| Performed | 393 (85.6) |
| Positive | 338 (73.6) (86.0b) |
| Negative | 55 (12.0) (14.0b) |
| Not performed | 66 (14.4) |
| TTF-1 | |
| Performed | 33 (7.2) |
| Positive | 3 (0.7) (9.1b) |
| Negative | 30 (6.5) (90.9b) |
| Not performed | 426 (92.8) |
| Biopsy material, n (%), (n=458) | |
| Primary tumor | 227 (49.6) |
| Primary tumor + metastasis | 95 (20.7) |
| Metastasis | 136 (29.7) |
| Biopsy location, n (%), (n=457) | |
| Intestines | 183 (40.1) |
| Liver | 124 (27.1) |
| Lymph nodes | 18 (3.9) |
| Lung | - |
| Other | 132 (28.9) |
| Diagnostic studies, n (%) | |
| Chromogranin A in serum (n=459) | |
| Yes | 334 (72.8) |
| No | 104 (22.6) |
| Not performed | 21 (4.6) |
| 5-HIAA (n=460) | |
| Performed | 192 (41.7) |
| Positive | 71 (15.4) (37.0b) |
| Negative | 121 (26.3) (63.0b) |
| Not performed | 268 (58.3) |
| Peptides (n=460) | |
| Performed | 107 (23.3) |
| Positive | 43 (9.4) (40.2b) |
| Negative | 64 (13.9) (50.8b) |
| Not performed | 353 (76.7) |
| Octreoscan (n=460) | |
| Performed | 214 (46.5) |
| Positive | 169 (36.7) (79.0b) |
| Negative | 45 (9.8) (21.0b) |
| Not performed | 246 (53.5) |
| Ki67 (n=461) | |
| Reported | 340 (73.8) |
| Not reported | 121 (26.2) |
| Echocardiogram (n=460) | |
| Performed | 140 (30.4) |
| Carcinoid-positive | 31 (6.7) (22.1b) |
| Carcinoid-negative | 109 (23.7) (77.9b) |
| Not performed | 320 (69.6) |
a
Results higher than the number of patients are due to some patients undergoing >1 procedure.
b
Percentages of patients in whom the studies were conducted.
TTF-1, thyroid transcription factor; 5-HIAA, 5-hydroxyindoleacetic acid.